After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
In response to a request from the European Medicines Agency following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy gene therapy Elevidys.
In response to a request from the European Medicines Agency following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy gene therapy Elevidys.
